熱門資訊> 正文
Omega Therapeutics在Nature Communications中发布表观基因组控制器OTX-2002临床前数据
2024-09-17 19:13
- Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents in preclinical models of HCC
- Proof-of-concept data for OTX-2002 support potential of epigenomic controllers to effectively target and modulate expression of nearly any human gene, including historically undruggable targets
- Data further validate the OMEGA platform's potential to rapidly and prospectively design, develop and advance programmable epigenomic mRNA medicines for the treatment of a broad range of diseases
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。